Nuvilex Appoints Dr. Matthias Löhr as Chairman of Scientific Advisory Board
October 06 2014 - 9:00AM
InvestorsHub NewsWire
SILVER SPRING, MD - October 06, 2014 - InvestorsHub
NewsWire - Nuvilex, Inc. (OTCQB:
NVLX), a clinical-stage biotechnology company providing
cell therapy solutions for the treatment of
diseases, announced today that noted European
gastroenterologist and oncologist Dr. Matthias Löhr has agreed
to serve as Chairman of the Nuvilex’s newly formed Scientific
Advisory Board.
Dr. Löhr has been a full professor of gastroenterology and
hepatology at the famed Karolinska Institute in Stockholm,
Sweden, since 2007. He has served as Professor of Molecular
Gastroenterology at the University of Heidelberg and was the
Head of the Molecular Gastroenterology Unit at the German
Cancer
Research Center. Dr. Löhr has also worked as a translational
scientist and Principal Investigator in clinical studies in
gastrointestinal oncology for many years and completed a
postdoctoral fellowship at the Scripps Clinic & Research
Foundation in La Jolla, California. Following receipt of his M.D.
degree, Dr. Löhr served a residency in pathology and a
residency in internal medicine and gastroenterology in Erlangen and
Rostock in Germany, where he also served as an Assistant
Professor.
“It is my firm belief the Cell-in-a-Box® technology will prove to
be of great value for the development of treatments for
pancreatic and other cancers, and its possible role in a treatment
for insulin-dependent diabetes is particularly intriguing. It
is a pleasure to chair Nuvilex’s Scientific Advisory Board. I
look forward to working with the Nuvilex team to help bring
this important technology to fruition,” commented Dr. Löhr.
Dr. Löhr served as Principal Investigator for the Phase 1/2 and
Phase 2 clinical trials of Nuvilex’s pancreatic cancer
treatment that were completed in the early 2000s. Not only is he
familiar with the Cell-in-a-Box® live cell encapsulation
technology that forms the core of Nuvilex’s pancreatic cancer
treatment, but he has actually used Nuvilex’s treatment (the
combination of Cell-in-a-Box® capsules with low doses of
the anticancer drug ifosfamide) in clinical trials in patients
with advanced, inoperable pancreatic cancer. Dr. Löhr
previously agreed to serve as a consultant to Nuvilex in connection
with its development of treatments
for pancreatic cancer and diabetes based on the Cell-in-a-Box®
technology. He has expertise in the treatment of both diseases
in addition to thoroughly understanding the Cell-in-a-Box®
technology and its use in a clinical setting.
Nuvilex’s CEO and President, Kenneth L. Waggoner, commented, “We
are extremely pleased that Dr. Löhr, one of Europe’s leading
gastroenterologists and oncologists, has agreed to serve as
Chairman of our Scientific Advisory Board. Dr. Löhr’s
knowledge of the Cell-in-a-Box® technology and his experience
in
using Nuvilex’s pancreatic cancer treatment in the clinic make him
the ideal choice for this appointment. This belief is
bolstered by the fact that Dr. Löhr is an expert in pancreatic
cancer and has a keen interest and experience in the treatment
of diabetes – both key areas of development for Nuvilex.”
About Nuvilex
Nuvilex (OTCQB:
NVLX) is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based live
cell encapsulation technology known as Cell-in-a-Box®. This
unique and patented technology will be used as a
platform upon which treatments for several types of cancer,
including advanced, inoperable pancreatic cancer, and diabetes
are being built. Nuvilex's treatment for pancreatic cancer involves
low doses of the well-known anticancer prodrug ifosfamide,
together with encapsulated live cells, which convert
ifosfamide into its active or "cancer-killing" form. In
concert with these efforts, Nuvilex is working towards
improving the quality of life for patients with advanced
pancreatic cancer and on treatments for other cancers.
In addition, Nuvilex is developing cancer treatments based
upon chemical constituents of marijuana known as cannabinoids.
To do so, Nuvilex is examining ways to exploit the benefits of the
Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of cannabinoids, while minimizing or
outright eliminating the debilitating side effects usually
associated with cancer treatments. This provides Nuvilex
a unique opportunity to develop “green” approaches to fighting
deadly cancers, such as those of the pancreas, brain and
breast that affect hundreds of thousands of individuals worldwide
every year.
Safe Harbor
This press release may contain forward-looking statements regarding
Nuvilex and its future events and results that involve
inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to Nuvilex or its management, are
intended to
identify forward-looking statements. Important factors, many of
which are beyond the control of Nuvilex, that could cause actual
results to differ materially from those set forth in the
forward-looking statements include Nuvilex's ability to
continue as a going concern, delays or unsuccessful results in
clinical trials or
flaws or defects regarding its product candidates, changes in
relevant legislation or regulatory requirements, uncertainty
of protection of Nuvilex's intellectual property and Nuvilex's
continued ability to raise capital. Nuvilex does not assume
any obligation to update any of these forward-looking
statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be
obtained by contacting
Investor Relations.
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 106
cmtschullt@bplifescience.com